Current treatments of the anxiety disorders in adults (Q33795331)

29 July 2017

1 reference

title

Current treatments of the anxiety disorders in adults (English)

1 reference

29 July 2017

Ballenger JC

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

29 July 2017

published in

Biological Psychiatry

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

1579-1594

1 reference

Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Cingulotomy for intractable obsessive-compulsive disorder. Prospective long-term follow-up of 18 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Behavioral treatment of panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Advances in the psychosocial treatment of anxiety disorders. Implications for national health care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Moclobemide in Social Phobia: A Pilot Open Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Post-traumatic stress disorder following combat exposure: clinical features and psychopharmacological treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Safety and efficacy of long-term diazepam therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Objective determination of benzodiazepine use and abuse in alcoholics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

A cognitive approach to panic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Drug therapy of post-traumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Post-traumatic stress disorder in the community: an epidemiological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Predicting response to amitriptyline in posttraumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Treatment of social phobia with clonazepam and placebo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Drug therapy. Benzodiazepines (first of two parts).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Drug therapy. Benzodiazepines (second of two parts).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Outcome of treatment for post-traumatic stress disorder in a primary care unit serving Vietnam veterans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Cognitive?behavioral group treatment for social phobia: Effectiveness at five-year followup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

The private practice psychologist and manual-based treatments: post-traumatic stress disorder secondary to motor vehicle accidents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Long-term use of diazepam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Stress response syndromes. Character style and dynamic psychotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Neurotic illness and its response to anxiolytic and antidepressant treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Abuse potential of halazepam and of diazepam in patients recently treated for acute alcohol withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

The concept of the Second Generation program in the treatment of post-traumatic stress disorder among Vietnam veterans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Social phobia. Longitudinal course and long-term outcome of cognitive-behavioral treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Long-term follow-up after a drug trial for panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Secondary depression in panic disorder and agoraphobia. II. Dimensions of depressive symptomatology and their response to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Tricyclic therapy of the DSM-III anxiety disorders: a review with implications for further research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

The treatment of panic disorder in a clinical setting: a 12-month naturalistic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Psychological treatment of panic: work in progress on outcome, active ingredients, and follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Are there Anticompulsive or Antiphobic Drugs? Review of the Evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Home self-assessment of obsessive-compulsive disorder. Use of a manual and a computer-conducted telephone interview: two UK-US studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Brief standard self-rating for phobic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Cognitive-behavioral group therapy for panic disorder in the general clinical setting: a naturalistic study with 1-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Prevalence and Correlates of the Long-term Regular Use of Anxiolytics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

The treatment of social phobia: the differential effectiveness of exposure in vivo and an integration of exposure in vivo, rational emotive therapy and social skills training

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

An open trial of moclobemide in the treatment of post-traumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Applied relaxation: description of a coping technique and review of controlled studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Applied relaxation, exposure in vivo and cognitive methods in the treatment of panic disorder with agoraphobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Discontinuation of benzodiazepine treatment: efficacy of cognitive- behavioral therapy for patients with panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Sertraline in the treatment of panic disorder: a double-blind multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Long-term Diazepam Therapy and Clinical Outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Paroxetine efficacy in the treatment of generalized anxiety disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Sertraline in the treatment of rape victims with posttraumatic stress disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Course and outcome in panic disorder: a review of recent follow-up studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Treatment of posttraumatic stress disorder: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Eye movement desensitization: a new treatment for post-traumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Multicenter Collaborative Panic Disorder Severity Scale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Effects of psychotherapeutic treatments for PTSD: a meta-analysis of controlled clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

A controlled trial of phenelzine in posttraumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Treatment of Vietnam War veterans with PTSD: a comparison of eye movement desensitization and reprocessing, biofeedback, and relaxation training

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Efficacy of treatments for posttraumatic stress disorder. An empirical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Pharmacotherapy for post-traumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

A 2-year follow-up of social phobia. Status after a brief medication trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Cognitive Restructuring in the Treatment of Social Phobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Group cognitive-behavioral treatment of panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

A multicomponent behavioral treatment for social phobia: social effectiveness therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Medication side effects in anxious patients: negative placebo responses?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Nefazodone in social phobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

A Meta-Analysis of the Treatment of Panic Disorder with or without Agoraphobia: A Comparison of Psychopharmacological, Cognitive-Behavioral, and Combination Treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Eye-movement desensitisation. Symptom change in post-traumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Social phobia: long-term treatment outcome and prediction of response--a moclobemide study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Pharmacotherapy of Social Phobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Exposure in vivo vs social skills training for social phobia: long-term outcome and differential effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Behavior Therapy, Supportive Psychotherapy, Imipramine, and Phobias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Response characteristics to antidepressants and placebo in post-traumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Open trial of nefazodone for combat-related posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Treatment of panic and agoraphobia. An integrative review

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Cognitive-Behavior Therapy for Panic Disorder Delivered by Psychopharmacologically Oriented Clinicians

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Treatment of nonphobic anxiety disorders: a comparison of nondirective, cognitive, and coping desensitization therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Long-term outcome in cognitive-behavioral treatment of panic disorder: Clinical predictors and alternative strategies for assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Cognitive therapy of anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

A meta-analysis of treatments for panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Treatment of posttraumatic stress disorder in rape victims: a comparison between cognitive-behavioral procedures and counseling

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Relapse prevention program for treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

Treatment of severe social phobia: effects of guided exposure with and without cognitive restructuring

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900220-6

7 January 2021

10.1016/S0006-3223(99)00220-6

Identifiers

DOI

1 reference

29 July 2017

1 reference